Hemodiafiltration (HDF) was created in the late 1970s to combine the best of hemodialysis (HD) and hemofiltration, i.e. superior removal of both small and large solutes. Thus, optimal conditions for both diffusion and convection are required. The need for large volumes of sterile fluid has shaped the evolution of HDF, and regulatory issues around systems for on-line fluid preparation have delayed the clinical development of the therapy. Not until such systems became generally available in the mid-1990s was it possible to increase the efficiency of HDF therapy to match and exceed the upgrade that had taken place for HD. Results from recent studies indicate that the potential for improving the outcome of dialysis lies in increasing the convective clearance of HDF above that of high-flux HD.

Keywords:
Hemodiafiltration, Classic hemodiafiltration, On-line hemodiafiltration, Convection volume
1.
Babb AL, Popovich RP, Christopher TG, Scribner BH: The genesis of the square meter-hour hypothesis. Trans Amer Soc Artif Int Organs 1971;XVII:81-91.
2.
Henderson LW, Colton CK, Ford CA: Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality. J Clin Lab Med 1975;85:372-391.
3.
Leypoldt JK: Solute fluxes in different treatment modalities. Nephrol Dial Transplant 2000;15(suppl 1):3-9.
4.
Leber HW, Wizemann V, Goubeaud G, Rawer P, Schütterle G: Simultaneous hemofiltration/hemodialysis: an effective alternative to hemofiltration and conventional hemodialysis in the treatment of uremic patients. Clin Nephrol 1978;9:115-121.
5.
Wizemann V, Rawer P, Schmidt H, Techert F, Schütterle G: Efficiency of hemodialysis, hemofiltration, hemodiafiltration; in Schütterle G, Wizemann V, Seyffart G (eds): Hemodiafiltration. Proceedings 1. Symposion Giessen 1981. Oberursel, Verlag Hygieneplan, 1982, pp 25-36.
6.
Wizemann V, Rawer P, Schütterle G: Ultrashort hemodiafiltration, long term efficiency and hemodynamic tolerance. Proc EDTA 1982;19:175-181.
7.
Wizemann V, Kramer W: Short-term dialysis - long-term complications. Blood Purif 1987;5:193-201.
8.
Gurland HJ, Davison AM, Bonomini V, Falkenhagen D, Hansen S, Kishimoto T, Lysaght MJ, Moran J, Valek A: Definitions and terminology in biocompatibility. Nephrol Dial Transplant 1994;9(suppl 2):4-10.
9.
Ledebo I, Blankestijn PJ: Hemodiafiltration - optimal efficiency and safety. NDT Plus 2010;3:8-16.
10.
Henderson LW, Beans E: Successful production of sterile, pyrogen-free electrolyte solution by ultrafiltration. Kidney Int 1978;14:522-525.
11.
Ledebo I: On-line preparation of solutions for dialysis: practical aspects versus safety and regulations. J Am Soc Nephrol 2002;13:S78-S83.
12.
Ledebo I: Fluid in bags for hemodiafiltration; in Ronco C, Canaud B, Aljama P (eds): Hemodiafiltration. Contrib Nephrol. Basel, Karger, 2007, vol 158, pp 87-93.
13.
Biasiolo S, Feriani M, Chiaramonte S, Cavallini L, Cesaro A, Fazion S, Petrosino L, Porena P, Zambrello A: Different buffers for hemodiafiltration. A controlled study. Int J Artif Organs 1989;12:25-30.
14.
Shinzato T, Sezaki R, Usuda M, Maeda K, Ohbayashi S, Toyota T: Infusion-free hemodiafiltration: simultaneous hemofiltration and dialysis with no need for infusion fluid. Artif Organs 1982;6:453-456.
15.
von Albertini B, Miller JH, Gardner PW, Shinaberger JH: High-flux hemodiafiltration: under six hours/week treatment. Trans Am Soc Artif Intern Organs 1984;30:227-231.
16.
Nakai S, Kunitoshi I, Tabei K, Kubo K, Masakane I, Fushimi K, Kikushi K, Shinzato T, Sanaka T, Akiba T: Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 2001;38(suppl 1):S212-S216.
17.
Bosch JP, Lew SQ, Barlee V, Mishkin GJ, von Albertini B: Clinical use of high-efficiency hemodialysis treatments: long-term assessment. Hemodial Int 2006;10:73-81.
18.
Cioni L, Palmarini D, Pilone N, Rindi P: High-flux hemodiafiltration: 5 years experience. Blood Purif 1989;7:197-202.
19.
Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G, the Italian Cooperative Dialysis Study Group: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996;30:1293-1302.
20.
Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P, D'Haenens P: On-line hemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant 2000;15(suppl 1):49-54.
21.
Yamashita AC: New dialysis membrane for removal of middle molecule uremic toxins. Am J Kidney Dis 2001;38(suppl 1):217-219.
22.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, the Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
23.
Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-2093.
24.
Joyeux V, Sijpkens Y, Haddj-Elmrabet A, Bijvoet AJ, Nilsson L-G: Optimized convective transport with automated pressure control in on-line postdilution hemodiafiltration. Int J Artif Organs 2008;31:928-936.
25.
Panichi V, De Ferrari G, Saffioti S, Sidoti A, Biagioli M, Bianchi S, Imperiali P, Gabbrielli C, Conti P, Patrone P, Falqui V, Rombolà G, Mura C, Icardi A, Mulas D, Rosati A, Santori F, Mannarino A, Tomei V, Bertucci A, Steckiph D, Palla R: Divert to ULTRA: differences in infused volumes and clearance in two on-line hemodiafiltration treatments. Int J Artif Organs 2012;35:435-443.
26.
Pedrini LA, De Christofaro V: On-line mixed hemodiafiltration with feedback for ultrafiltration control: effect on middle molecule removal. Kidney Int 2003;64:1505-1513.
27.
International Organization for Standardization: Quality of dialysis fluid for hemodialysis and related therapies (ISO 11663:2009). Geneva, International Organization for Standardization, 2009.
28.
Ronco C: Evolution of hemodiafiltration; in Ronco C, Canaud B, Aljama P (eds): Hemodiafiltration. Contrib Nephrol. Basel, Karger, 2007, vol 158, pp 9-19.
29.
Ledebo I, Ronco C: The best dialysis therapy? Results from an international survey among nephrology professionals. NDT Plus 2008;6:403-408.
30.
Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazirac AH, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, Ter Wee PM, Blankestijn PB, the CONTRAST investigators: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcome. J Am Soc Nephrol 2012;23:1087-1096.
31.
Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, Hur E, Demirci MS, Demirci C, Duman S, Basci A, Adam SM, Isik IO, Zengin M, Suleymanlar G, Yilmaz ME, Ozkahya M, the Turkish Online Hemodiafiltration Study: Mortality and cardiovascular events in on-line hemodiafiltration compared to high-flux dialysis: result from the Turkish online hemodiafiltration study. Nephrol Dial Transplant 2013;28:192-202.
32.
Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Forester A, Soler J, Galceran JM, Martinez-Castelao A, the online hemodiafiltration study group from the Catalan Society of Nephrology: Design and patient characteristics of ESHOL study, a Catalonian prospective randomized study. J Nephrol 2011;24:196-202.
33.
Tattersall JE, Ward RA, the EUDIAL group: Online hemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant, accepted.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.